CA1089457A - 5-nor-bicyclomycin-5-one derivatives - Google Patents
5-nor-bicyclomycin-5-one derivativesInfo
- Publication number
- CA1089457A CA1089457A CA278,748A CA278748A CA1089457A CA 1089457 A CA1089457 A CA 1089457A CA 278748 A CA278748 A CA 278748A CA 1089457 A CA1089457 A CA 1089457A
- Authority
- CA
- Canada
- Prior art keywords
- lower alkyl
- phenyl
- formula
- bicyclomycin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 71
- -1 2-tetrahydropyranyl Chemical group 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 239000007858 starting material Substances 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 10
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 125000001589 carboacyl group Chemical group 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- NCXMCIMXTASCLP-UHFFFAOYSA-N 5-oxa-8,10-diazabicyclo[4.2.2]decane Chemical class C1NC2CNC1OCCC2 NCXMCIMXTASCLP-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 125000001118 alkylidene group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 150000007659 semicarbazones Chemical class 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 3
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims 2
- 125000000676 alkoxyimino group Chemical group 0.000 claims 1
- DDNYYGSSEPOGRP-UHFFFAOYSA-N methyl 2-aminooxyacetate Chemical compound COC(=O)CON DDNYYGSSEPOGRP-UHFFFAOYSA-N 0.000 claims 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract description 2
- 125000005842 heteroatom Chemical group 0.000 abstract description 2
- 229930195733 hydrocarbon Natural products 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 229940088710 antibiotic agent Drugs 0.000 abstract 2
- 241000588921 Enterobacteriaceae Species 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 229960001866 silicon dioxide Drugs 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 229940093499 ethyl acetate Drugs 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000010828 elution Methods 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- WOUDXEYYJPOSNE-VKZDFBPFSA-N bicozamycin Chemical compound N1C(=O)[C@@]2(O)NC(=O)[C@]1([C@@H](O)[C@@](O)(CO)C)OCCC2=C WOUDXEYYJPOSNE-VKZDFBPFSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 239000000155 melt Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 5
- WOUDXEYYJPOSNE-UHFFFAOYSA-N bicyclomycin Natural products N1C(=O)C2(O)NC(=O)C1(C(O)C(O)(CO)C)OCCC2=C WOUDXEYYJPOSNE-UHFFFAOYSA-N 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000006385 ozonation reaction Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000334216 Proteus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- SPUACDWLOLSOQO-UHFFFAOYSA-M methoxyazanium;chloride Chemical compound [Cl-].CO[NH3+] SPUACDWLOLSOQO-UHFFFAOYSA-M 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- NDXLVXDHVHWYFR-UHFFFAOYSA-N 2-pyridin-1-ium-1-ylacetohydrazide;chloride Chemical compound [Cl-].NNC(=O)C[N+]1=CC=CC=C1 NDXLVXDHVHWYFR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012505 colouration Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007248 oxidative elimination reaction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- OBXBQDQBTXIDCA-UHFFFAOYSA-N 2-(dimethylamino)acetohydrazide;hydron;chloride Chemical compound Cl.CN(C)CC(=O)NN OBXBQDQBTXIDCA-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FPWYXHKGPQQAAG-UHFFFAOYSA-N 3-oxodecanal Chemical compound CCCCCCCC(=O)CC=O FPWYXHKGPQQAAG-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000151018 Maranta arundinacea Species 0.000 description 1
- 235000010804 Maranta arundinacea Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 235000012419 Thalia geniculata Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940045971 anti bac Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PWAPCRSSMCLZHG-UHFFFAOYSA-N cyclopentylidene Chemical group [C]1CCCC1 PWAPCRSSMCLZHG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- VYSYZMNJHYOXGN-UHFFFAOYSA-N ethyl n-aminocarbamate Chemical compound CCOC(=O)NN VYSYZMNJHYOXGN-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002561 ketenes Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Abstract of the Disclosure Derivatives of 5-norbicyclomycin of the formula
Description
~U~ t7 ~ 2 --The present invention relates to bicyclic compounds having the basic skeleton of the 2-oxa-7,9-diazabicyclo[4,2,2]decane of the formula 6 5 : :
7 N ~ ~ 4 8 ~ ~ 3 .1 2 and, in particular, derivatives of the 5-norbicycl~ycin of the formula d ~- R
OR N/
C`O CH2 H--C--ORa (I) CH3--C--ORb wherein each of Ra, Rb, Rc and Rd individually represents ~ ?~
hydrogen atom or oxa-(lower alkyl), oxa-~lower cycloalkyl), lower alkanoyl, benzoyl, lower alkoxycarbonyl, or any two of the symbols Ra, Rb and Rc together represent carbonyl, lower alkylidene, or lower cycloalkylidene, R represents hydrogen or -~
lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy, lower alkanoyloxy, amino, di-(lower alkyl)-amino, ~ :
carboxy or lower alkoxycarbonyl, or represents phenyl or phenvl- ~:
(lower alkyl), or phenyl or phenyl-(lower alkyl) whose ring is ,Ç~
.
., , . ~
~ . . . ~ ~ . . . .. . .
a~lS~
substituted by halogen, nitro, lower alkyl or lower alkoxy, or represents acyl derived from a lower alkanesulfonic acld, benzenesulfonic acid or from benzenesulfonic acid whose phenyl ring is substituted as indicated hereinabove, or an~inocar-bonyl which is unsubstituted or N-substituted by lower alkyl r or represents lower alkoxycarbonyl or acyl derived from a carboxylic acid derived from any of the above-defined unsub-stituted or substituted lower alkyl, phenyl or phenyl-~lower alkyl) radicals or from a pyridyl or pyridinio-(lower alkyl) radical, and X represents a bivalent group of the formula -O- or -NH-, and of pharmaceutically acceptable salts of such a compound, provided it contains a salt-forming group, and also to a process for the manufacture of said compounds and to preparations which contain them and to the use of the latter, as well as to therapeutic methods of combating in-fectious diseases which comprise the use of these compounds and preparations.
In the above c~mpounds of the formula I, the group ~X-R is ~y~- or a _ -oriented with respect to the rest of the molecule, ~or exa~ple in relation to the 6-hydroxyl group. Unless other-wise specifically stated, a process product can be both a mixture of both isomeric forms and an individual isomer.
An example for a phenyl lower alkylgroup isthe trityl group, examples for a2-oxaalkylor 2-oxacycloalkyl group are in particular ~0~ 7 a l-butoxyethyl or 2-tetrahydropyranyl group.
Unless stated to the contrary, the term "lower" used through-out this specification to qualify organic groups and radicals means that these contain not more than 7, preferably not more than 4, carbon atoms.
In an alkylidene radical two free valencies originate from a single carbon atom.
Examples of lower alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl, as well as n-pentyl, isopentyl, n-hexyl, isohexyl or n-heptyl.
Examples of Lower alkylidene radicals are methylene, iso-propylidene or lsobutylidene.
In a cycloalkylidene radical two free valencies originate from a single carbon atom. ;
Examples of lower cycloalkyl radicals are cyclopropyl, cyclo-butyl, cyclopentyl, cyclohexyl and cycloheptyl, as well as bicyclo[2,2,2]octyl, 2-bicyclo~2,2,1]heptyl, and also 1-, 2-or 3-methylcyclopentyl, 4-tert.-butylcyclohexyl, 4~4-di-methylcyclohexyl, 2,4,6-trimethylcyclohexyl and 2,4,4,6-tetra- ;~`
methylcyclohexyl. Examples of cycloalkylidene groups are cyclopentylidene and cyclohexylidene radicals.
~ 5~7 Examples for phenyl-lower alkyl radicals are benzyl, 1- or 2-phenylethyl- 1-, 2- or 3-phenylpropyl, diphenylmethyl (viz.
benzhydryl) and trityl.
Examples for lower alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert.-butoxy. Examples for oxa-(lower alkoxy) groups ORa, ORb, ORC and ORd are lower alkoxy groups which are substituted especially in the l-position, as in the butoxyethoxy moiety, or in the 2-pos~tion, as in the 2-methoxy-ethoxy moiety. Examples for oxa-(lower cycloalkoxy) groups are 2-tetrahydrofuranyloxy and 2-~etrahydropyranyloxy.
Examples for an optionally halogenated lower alkanesulphonyl group are methanesulphonyl and trifluoromethanesulphonyl.
Examples for a substituted benzenesulphonyl group are p-toluenesulphonyl (i.e. tosyl), p-chlorobenzenesulphonyl, p-bromobenzenesulphonyl and 2,4-din:itrobenzenesulphonyl.
Examples for a lower alkoxycarbonyl group which i5 unsub-stituted or substituted in particular by lower alkyl, lower alkoxy, nitro and/or halogen, are methoxycarbonyl, ethoxy-carbonyl, tert.-butoxycarbonyl, 2,2,2-trichloroethoxycarbonyl and 2-iodoethoxycarbonyl. Acyl radicals of the following acids are particularly preferred: propionic, butyric, iso-butyric, valeric, isovaleric, capronic, trimethylacetic and diethylacetic acid, and, most preferably, acetic acid, but also corresponding halogenated lower alkanecarboxylic acids, '` ~`'' ` ' . - . ~ .. .
~ - . - . - .
- . . , - - : , .:: . -4S'~
-- 6 ~
such as chloroacetic acid, bromoacetic acid or ~-bromoiso-valeric acid, phenylacetic or phenylpropionic acld.
The compounds of the formula I, provided they contain salt- :
forming groups, can be in the form of salts, preferably physiologically tolerable salts. If a comp~und of the formula I contains an acid group, such as carboxyl, salts can be formed with bases, vi~. primarily metal or ammonium salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines. Suit~
able amines for the salt formation are in particular acyclic, ~
carbocyclic and carbocyclic-acyclic primary, secondary and, -most preferably, tertiary mono-, di- or polyamines, and hetero~
cyclic bases, such as~lower alkylamines, for example triethyl- :`
aminè, hydroxy-lower alkylamines, for ~xample 2-hydroxyethyl~
amine, di-(2~hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine~s or tri-(2-hydroxyethyl)-amine, basi.c aliphatic esters of car- .
boxylic acids, for example 2- (diethy~amino) -ethyl 4-aminoben- :
æoate, lower alkylenamines, for ex~mple l-ethylpiperidine, cycloalkylamines, for example dicyclohexylamine 3 or benæyl-amines, for example N,N'-dibenzylethylenediamine, and base~ ; :
of the pyridine type, for example pyridine, collidine or quino- ;;~.. ~.
line. Compounds of the fonmula I, which contain a basic group in the substituents,~can form addition salts, in particular acid addition salts, for example with inorganic acids, such as :~
hydrochloric acid, sulphuric acid or phosphoric acid, or wi~h ,`''' ~''''~ ' -~
~U8~
:
suitable organic carboxylic or sulphonic acids, for example trifluoroacetic acid. Compounds of the formula I whichcontain both an acid and a basic group ~s substituents,can alsobe in the form of an inner salt, i.e. in zwitterion form. Addition salts also comprise quaternary salts which are formed, for example, by addition of a hydrocarbon halide to a tertiary amino group or th~ aromatic nitrogen atom of an aromatic hetero-cyclic ring. Examples are the methanesulphona~e, ~he bromide or the chloride o a tri-lower alkylammonio compound~ such as a trimethylammonio or pyridinio compound.
The novel compounds of the present invention exhibit useful pharmacological, especially antibiotic, for example anti-bacterial, properties, and/or can be used as intermediates for obtaining sush compou~ds.
,~
Particularly preferred compounds are those of the formula ; ~ R
OH NJ
~H ~ CH2 ' (IA) O~
H- C~ OH
~ : .` .';, ~ g~S7 wherein RA represents hydrogen or lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy, lower alkanoyl-oxy, amino, di-(lower alkyl)-amino, carboxy or lower alkoxy-carbonyl, or represents phenyl or phenyl-(lower alkyl), or phenyl or phenyl-(lower alkyl) whose ring is substituted by halogen, nitro, lower alkyl or lower alkoxy, or represents acyl derived from a lower alkanesulfonic acid, benzenesul-sulfonic acid or from benzenasulfonic acid whose phenyl ring :
is substituted as indicated hereinabove, or aminocarbonyl :~
which is unsubstituted or substituted by lower alkyl, or represents lower alkoxycarbonyl or acyl derived from a car-boxylic acid derived from any of the above-defined unsub-stituted or c;ubstituted lower alkyl, phenyl or phenyl-(lower alkyl) radicals or from a pyridyl or pyridinio-(lower alkyl) radical, and X represents a group of the formula -O- or -NH-, or a pharmaceutically acceptable salt of such a compound, provided it contains a salt-forming group.
Examples for amino-lower alkyl radicals are 2-aminoethyl, 2-dimethylaminoethyl, 3-aminopropyl or 4-aminobutyl. Examples for hydroxy-lower alkyl radicals are hydroxymethyl, 2-hydroxy- .~ `
ethyl and 2-hydroxypropyl. Examples for lower alkanoyloxy--lower alkyl radicals are acetoxymethyl, 2-formyloxyethyl and
7 N ~ ~ 4 8 ~ ~ 3 .1 2 and, in particular, derivatives of the 5-norbicycl~ycin of the formula d ~- R
OR N/
C`O CH2 H--C--ORa (I) CH3--C--ORb wherein each of Ra, Rb, Rc and Rd individually represents ~ ?~
hydrogen atom or oxa-(lower alkyl), oxa-~lower cycloalkyl), lower alkanoyl, benzoyl, lower alkoxycarbonyl, or any two of the symbols Ra, Rb and Rc together represent carbonyl, lower alkylidene, or lower cycloalkylidene, R represents hydrogen or -~
lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy, lower alkanoyloxy, amino, di-(lower alkyl)-amino, ~ :
carboxy or lower alkoxycarbonyl, or represents phenyl or phenvl- ~:
(lower alkyl), or phenyl or phenyl-(lower alkyl) whose ring is ,Ç~
.
., , . ~
~ . . . ~ ~ . . . .. . .
a~lS~
substituted by halogen, nitro, lower alkyl or lower alkoxy, or represents acyl derived from a lower alkanesulfonic acld, benzenesulfonic acid or from benzenesulfonic acid whose phenyl ring is substituted as indicated hereinabove, or an~inocar-bonyl which is unsubstituted or N-substituted by lower alkyl r or represents lower alkoxycarbonyl or acyl derived from a carboxylic acid derived from any of the above-defined unsub-stituted or substituted lower alkyl, phenyl or phenyl-~lower alkyl) radicals or from a pyridyl or pyridinio-(lower alkyl) radical, and X represents a bivalent group of the formula -O- or -NH-, and of pharmaceutically acceptable salts of such a compound, provided it contains a salt-forming group, and also to a process for the manufacture of said compounds and to preparations which contain them and to the use of the latter, as well as to therapeutic methods of combating in-fectious diseases which comprise the use of these compounds and preparations.
In the above c~mpounds of the formula I, the group ~X-R is ~y~- or a _ -oriented with respect to the rest of the molecule, ~or exa~ple in relation to the 6-hydroxyl group. Unless other-wise specifically stated, a process product can be both a mixture of both isomeric forms and an individual isomer.
An example for a phenyl lower alkylgroup isthe trityl group, examples for a2-oxaalkylor 2-oxacycloalkyl group are in particular ~0~ 7 a l-butoxyethyl or 2-tetrahydropyranyl group.
Unless stated to the contrary, the term "lower" used through-out this specification to qualify organic groups and radicals means that these contain not more than 7, preferably not more than 4, carbon atoms.
In an alkylidene radical two free valencies originate from a single carbon atom.
Examples of lower alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl, as well as n-pentyl, isopentyl, n-hexyl, isohexyl or n-heptyl.
Examples of Lower alkylidene radicals are methylene, iso-propylidene or lsobutylidene.
In a cycloalkylidene radical two free valencies originate from a single carbon atom. ;
Examples of lower cycloalkyl radicals are cyclopropyl, cyclo-butyl, cyclopentyl, cyclohexyl and cycloheptyl, as well as bicyclo[2,2,2]octyl, 2-bicyclo~2,2,1]heptyl, and also 1-, 2-or 3-methylcyclopentyl, 4-tert.-butylcyclohexyl, 4~4-di-methylcyclohexyl, 2,4,6-trimethylcyclohexyl and 2,4,4,6-tetra- ;~`
methylcyclohexyl. Examples of cycloalkylidene groups are cyclopentylidene and cyclohexylidene radicals.
~ 5~7 Examples for phenyl-lower alkyl radicals are benzyl, 1- or 2-phenylethyl- 1-, 2- or 3-phenylpropyl, diphenylmethyl (viz.
benzhydryl) and trityl.
Examples for lower alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert.-butoxy. Examples for oxa-(lower alkoxy) groups ORa, ORb, ORC and ORd are lower alkoxy groups which are substituted especially in the l-position, as in the butoxyethoxy moiety, or in the 2-pos~tion, as in the 2-methoxy-ethoxy moiety. Examples for oxa-(lower cycloalkoxy) groups are 2-tetrahydrofuranyloxy and 2-~etrahydropyranyloxy.
Examples for an optionally halogenated lower alkanesulphonyl group are methanesulphonyl and trifluoromethanesulphonyl.
Examples for a substituted benzenesulphonyl group are p-toluenesulphonyl (i.e. tosyl), p-chlorobenzenesulphonyl, p-bromobenzenesulphonyl and 2,4-din:itrobenzenesulphonyl.
Examples for a lower alkoxycarbonyl group which i5 unsub-stituted or substituted in particular by lower alkyl, lower alkoxy, nitro and/or halogen, are methoxycarbonyl, ethoxy-carbonyl, tert.-butoxycarbonyl, 2,2,2-trichloroethoxycarbonyl and 2-iodoethoxycarbonyl. Acyl radicals of the following acids are particularly preferred: propionic, butyric, iso-butyric, valeric, isovaleric, capronic, trimethylacetic and diethylacetic acid, and, most preferably, acetic acid, but also corresponding halogenated lower alkanecarboxylic acids, '` ~`'' ` ' . - . ~ .. .
~ - . - . - .
- . . , - - : , .:: . -4S'~
-- 6 ~
such as chloroacetic acid, bromoacetic acid or ~-bromoiso-valeric acid, phenylacetic or phenylpropionic acld.
The compounds of the formula I, provided they contain salt- :
forming groups, can be in the form of salts, preferably physiologically tolerable salts. If a comp~und of the formula I contains an acid group, such as carboxyl, salts can be formed with bases, vi~. primarily metal or ammonium salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines. Suit~
able amines for the salt formation are in particular acyclic, ~
carbocyclic and carbocyclic-acyclic primary, secondary and, -most preferably, tertiary mono-, di- or polyamines, and hetero~
cyclic bases, such as~lower alkylamines, for example triethyl- :`
aminè, hydroxy-lower alkylamines, for ~xample 2-hydroxyethyl~
amine, di-(2~hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine~s or tri-(2-hydroxyethyl)-amine, basi.c aliphatic esters of car- .
boxylic acids, for example 2- (diethy~amino) -ethyl 4-aminoben- :
æoate, lower alkylenamines, for ex~mple l-ethylpiperidine, cycloalkylamines, for example dicyclohexylamine 3 or benæyl-amines, for example N,N'-dibenzylethylenediamine, and base~ ; :
of the pyridine type, for example pyridine, collidine or quino- ;;~.. ~.
line. Compounds of the fonmula I, which contain a basic group in the substituents,~can form addition salts, in particular acid addition salts, for example with inorganic acids, such as :~
hydrochloric acid, sulphuric acid or phosphoric acid, or wi~h ,`''' ~''''~ ' -~
~U8~
:
suitable organic carboxylic or sulphonic acids, for example trifluoroacetic acid. Compounds of the formula I whichcontain both an acid and a basic group ~s substituents,can alsobe in the form of an inner salt, i.e. in zwitterion form. Addition salts also comprise quaternary salts which are formed, for example, by addition of a hydrocarbon halide to a tertiary amino group or th~ aromatic nitrogen atom of an aromatic hetero-cyclic ring. Examples are the methanesulphona~e, ~he bromide or the chloride o a tri-lower alkylammonio compound~ such as a trimethylammonio or pyridinio compound.
The novel compounds of the present invention exhibit useful pharmacological, especially antibiotic, for example anti-bacterial, properties, and/or can be used as intermediates for obtaining sush compou~ds.
,~
Particularly preferred compounds are those of the formula ; ~ R
OH NJ
~H ~ CH2 ' (IA) O~
H- C~ OH
~ : .` .';, ~ g~S7 wherein RA represents hydrogen or lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy, lower alkanoyl-oxy, amino, di-(lower alkyl)-amino, carboxy or lower alkoxy-carbonyl, or represents phenyl or phenyl-(lower alkyl), or phenyl or phenyl-(lower alkyl) whose ring is substituted by halogen, nitro, lower alkyl or lower alkoxy, or represents acyl derived from a lower alkanesulfonic acid, benzenesul-sulfonic acid or from benzenasulfonic acid whose phenyl ring :
is substituted as indicated hereinabove, or aminocarbonyl :~
which is unsubstituted or substituted by lower alkyl, or represents lower alkoxycarbonyl or acyl derived from a car-boxylic acid derived from any of the above-defined unsub-stituted or c;ubstituted lower alkyl, phenyl or phenyl-(lower alkyl) radicals or from a pyridyl or pyridinio-(lower alkyl) radical, and X represents a group of the formula -O- or -NH-, or a pharmaceutically acceptable salt of such a compound, provided it contains a salt-forming group.
Examples for amino-lower alkyl radicals are 2-aminoethyl, 2-dimethylaminoethyl, 3-aminopropyl or 4-aminobutyl. Examples for hydroxy-lower alkyl radicals are hydroxymethyl, 2-hydroxy- .~ `
ethyl and 2-hydroxypropyl. Examples for lower alkanoyloxy--lower alkyl radicals are acetoxymethyl, 2-formyloxyethyl and
2-acetoxyethyl, and examples for lower alkoxy-lower alkyl ` :~
radicals are methoxymethyl, ethoxymethyl, 2-methoxyethyl and ~;
2-ethoxyethyl. ; -~.. ,~.. ~, ;
9~
g Carboxyl groups can be in the free form, as salts or as lower alkyl esters, in particular methyl and ethyl esters.
The novel compounds reveal useful pharmacological properties, as is shown both in the in vitro test and in animaltests.Thus the in vitro test results show them to have antibiotic, in particular antibac~erial, properties, for ex~mple against Enterobacteria (in concentrations of 0.025 to 0.5 mg/ml). In animal tests too, or against Proteus sp. (in concentrations of 0.1 to 0.5 mg/ml), for example on mice in doses of 16 to 100 mg/kg (subcutaneous administration) the novel com- ;
pounds show antibacterial properties against Escherichiacoli and Klebsiella, and, in doses of 20 to 700 mg/kg (subcuta~
neous administration), against Proteus sp. To be singled out for special mention is 5-methoxyimino-S-norbicyclomycin, i.e.
the compound of the formula IA, wherein -X-RA represents the methoxy group, for which an effective dose ED50 of 16 to ~`
20 mg/kg was found against Enterobacteria, for example Escherichia coli and Proteus sp., when administered subcuta-neously to mice. Bicyclomycin, to the contrary, is not suffi-ciently effective against Proteus. The novel compounds can therefore be used for example in the form of antibiotic preparations for the treatment of infectious diseases, or as preservatives, or as additives to animal feeds. In addition, ~
they can be used for the preparation of other compounds with ~-such an antibiotic action.
~ '~'' '' :' ~............................................................ ~;. ':`
L5 ~
The compounds of the formula I are obtained by reacting a 5-norbicyclomycin-S-one compound of the formula II
oRd O
/~ ' .~
~H ~ CH2 ,;
(~1 --0 / ( II) H--C--OR
CH3--C--oRb :,`.
wherein Ra, Rb, Rc and Rd are as defined in formula (I), with a co~pound of the formula . R-X-NH2 (III) .
wherein R and X are as already defined, or with a salt thereof, and, if desired, in a resultant compound~ removing or intro~
ducing one or more hydroxyl protectîve groups Ra, Rb, RCand/or Rd or converting them intoother hydroxylprotective gxoups,and,if ~ ~
desired, within the definition of the final products,converting ~ -a resul~ant compound into another compound, and/or,ifdesired, ~ :
converting a resultant compound with a salt forming group into the free compound or into another salt, and/or, if desired, ;~
s~parating individual isomers from a Fesultant isomer mixture. ~
':' `
:-. :- . -. :.. . -: : .. - . . : -, .. , . . ~ ~
Preferably, 5-norbicyclomycin-5-one, which has free hydroxyl groups, is used as s~arting material of the formula II.
Starting materials of the formula III are hydroxylamine and 0-substituted hydroxylamines of the formula R-O-NH2 (IIIa) wherein R is as defined above, and the corresponding acid addition salts. Starting materials of the formula III are also hydrazine or hydrazine hydrate and, in particular mono-substituted hydrazines, including semicarbazide, and the corresponding salts.
.~'.
They are characterised by the formula R
~-NH2 (IIIb) H
wherein R is as already defined herein. Salts of compounds of the formula III are primarily acid additions salts, in par-ticular with mineral acids, such as hydrohalic acids, for example hydrochloric or hydrobromic acid, or sulphuric acid.
: ` .
The above reaction is carried out in a manner known per se, `~
and, when using acid addition salts of compounds oftheormula ; III, in the presence o a basic reagent. Suitable bases are inorganic bases, such as carbonates or hydrogen carbonates of alkali metals or alkaline earth metals, for exa~ple sodium :~:
~. .,, ; ~ ~
`
hydrogen carbonate, or organic bases, for example tertiary organic bases, such as correspondin~ heterocyclic bases, for example pyridine or quinoline, or tertiary aliphatic, cyclo- :
aliphatic or aromatic amines, for example tri-loweralkylamine such as triethylamine, and also alkali metal or alkalineearth metal salts of organic carboxylic acids, such as lower alkane-carboxylic acids, for example acetic acid,such as sodium acetate. ~
The reaction is preferably carried out in the presence of a ~ ~.
suitable solvent or diluent, such as an alcohol, for example .
a lower alkanol, such as methanol or ethanol, an ether, such as a cyclic ether, for example tetrahydrofurane or dioxane, .
or an ether of a glycol, such as a lower alkyl etherof aglycol or polyglycol, for example ethylene glycol dimethyl ether or . .
diethylene glycol dimethyl ether, or a halogenatedhydrocarbon, such as a chlorinated alkane, for example methylene chloride, :
and water, or a solvent or diluent mixture) with cooling or ~.
preferably with heating, for exampl~3 at temperatures of 20 .
to 100C, and, if appropriate, in a closed reaction vessel ~-~
and/or in an inert gas atmosphere, for example in a nitrogen or argon atmosphere. ~ :
:'`~` ' In the process of the present invention and also in any addi-tional steps which it may be necessary to carry out, free ~unctional groups which are present in the starting materials .
~ ~4~ 5 or in the c~mpounds obtained in accordance with the process and which do not participate in the reaction, for example free amino groups in the group R, can, if necessary, be temporarily protected by acylation, tritylation or silylation, and, in particular, free hydroxyl groups in the bicyclomycin skeleton can be protected for example by etherification or esterifi-cation in a manner known per se, and, when the reaction is complete, set free, if desired, individually or together.
Thus, for example, hydroxyl groups which are protected as tetrahydropyranyl ether, for example in the 1'-, 3'- and/or 6-position, can be set free by conventional acid catalysed hydrolysis.
Resultant compounds of the formula I can be converted in a manner known per se into other compounds of the formula I.
For example, in a compound of the formula I, in which R in the grouping -NH-R represents hydrogen, and each of Ra, Rb and Rc is preferably different fr~m hydrogen~ the amino group can be substituted by methods which are known per se, in par~icular acylated, in a manner known per se, by treatment with acids, such as carboxylic acids, or reactive derivatives thereof, such as anhydrides, halides, for example chlorides, :~
and ketenes.
, ,. !; ~.
1~ ~ 9 ~ 5 7 It is also possible, for example in a compound ofthe formula I, wherein R in the grouping -O-R represents hydrogen, to substi-tute, preferably to alkylate, the free hydroxyl groupby methods which are known per se. In particular, a corresponding oxime with a free hydroxyl group can be treated in a mannerknown per se with a diaæoalkane, preferably diazomethane, preferably avoiding a large excess of the reactant and inappropriately long reaction tlmes.
Salts of compounds of the formula I càn be prepared in a manner ;~
known per se. Thus salts of compounds of the formula I with an acid grouping can be formed for example by treatment with metal~;
compounds, such as hydroxides, carbonates and hydrocarbonates of alkali metals or alkaline earth metals, andalsowith alkali ~`
metal salts of suitable carboxylic acids,for examplethe sodium salt of -ethylcaproic acid, or with ammonia or a suitable organic amine, preferably using stoichiometric amounts or only a small excess of the salt-forming agent. Acid addition salts ~
of compounds of the formula I with basic groups are obtained ~ ;
in similar manner, for example by treatment with an acid or a suitable anion exchanger. Inner salts of compounds o the formula I which contain a salt-forming amino group and a free carboxyl group, can be formed for example by neutralising salts, such as acid addition sal~s, to the isoelectric point, or example with weak bases, or by treatment with liquid ion exchangers.
-- . - , Salts can be converted in the cust:omary manner in~o the free compounds, metal and ammonium salts for example by treatment with suitable acids, and acid addition salts or example by treatment with a suitable base.
Resultant mixtures of stereoisomers can be separated into the individual isomers by methods which are known per se, for example by fractional crystallisation, adsorption chromato-graphy ~column or thin-layer chromatography), or other appropriate methods of separation.
The process also comprises those embodiments of the invention in which compounds obtained as intermediates are used as ~; `
starting materials and the remaining process steps are carried out therewith or in which the process is interrupted at any stage, or starting materials can be used in the form of deri-vatives or formed du_ing the reaction.
Preferably, the starting materials and reaction conditions are so chosen that the compounds referred to at the outset as~eing especially preferred are obtained.
The starting materials of the formula II used in accordance `
with the invention are novel They can be prepared forexamplc by oxidative elimination of the methylene group in a compound of the bicyclomycin type of the formula :.
'.
-- 16 - :
oRd ' ~' 2 ::~
~ ~H2 . ~
(~ /H2 ~ .. '' O (IV) H- C- ORa CH3- C - oRb wherein Ra9 Rb, Rc and Rd are as previously defined herein, and, if desired, in a resultant compound, introducing or-re-moving one or more hydroxyl protective groups Ra, Rb, Rc and/or .Rd or converting them into other hydroxyl protective groups. ::
The oxidative elimination of the methylene group can be accom~
plished in a manner known per se, for example byoxidatiDn with potassium permanganate or by hydroxylation, for example with osmi~m tetroxide, and subsequent glycol cleavage, or exampl with periodic acid or lead(IV) salts, the hydroxyl groups of the starting material being preferably protected and optionally ~ :
subsequently removed. Advan~ageously, the methylene group is removed by ozonisation, because, among other reasons, unpro~
tected hydroxyl groups are not affected.
. ;
"~
~0~3'~57 The ozonisation can be carried out in a manner known per se, for example by introducing a flow of oxygen which contains ozone into a solution of a bicyclomycin co~pound in a solvent which is inert to ozone until the theoretical amount of ozone has been consumed, and b~ decomposing the resultant ozonide thermally or by hydrolysis, reduction or oxida~ion. Suitable solvents ~or ozonisation are polyhalogenated, in particular chlorinated, lower alkanes, such as dichloromethane, chlorofo and dichloromethane, and in particular lower alkanols, such as me~hanol and ethanol, lower alkanecarboxylic acids,such as acetic acid, butyric acid, and preferably propionic acid, and the esters thereof with lower alkanols, such as ethyl acetate, as well as mixtures of such solvents. Preferred media are solvents and solvent mixtures which remain liquid even at low temperatures, for example below -20C and preferably also below -50C, and which still retain a good dissolving power for the -starting materials to be oæonised. ~he ozonisation is carried out at decreased temperature, for example between +10 and -80C, preferably between -18 and -70C. Normally the reac- ~ `~
tion is carried out with a small excess of ozone, which can be easily detected by the residual blue colouration of the reaction mixture. The decomposition of the resultantozonide is effected in the present process preferably by adding dimethyl sulphide, after which the reaction mixture isbrought ~`
to room temperature. The presence of water, for example of ;~
.~ ~' ., . .~ ~ _ __ _ _ _ _ . _ . .. .. _. __ _. _ _ _ .. ,. _ ,_ .
- ~o~
moisture or ~ater of crystallisation, does not affect these reactions.
~ree bicyclomycin of the formula IV, wherein Ra, ~b,RC and Rd represen~ hydrogen atoms, is.preferably used as starting material for the removal of the methylene group byozonolysis.
However, it is also possible to use corresponding derivatives, ;
fox example 1',3',6-tri-tetrahydropyranyl ether, with equal success.
The pharmacologically useful compounds of the present invention :;
can be used, for example, for the manufacture of pharmaceutlcal preparations which contain an effective amount of the active ;
substance together or in admixture with inorganic or organic ~:
solid or liquid pharmacologically useful carriers, which are suitable preferably for enteral or parenteral administration.
~ ~, Tablets or gelatin capsules are therefore used which contain the active substance together with diluents, for example lactose, dextrose, saccharose, mannitol, sorbitol, cellulose and/or glycin, and lubricants, for example silica, talc, stearic acid or salts thereof, such as magnesium or calcium :~
stearate, and/or polyethylene glycol. Tablets also contain binding agents, ~or example magnesium aluminium silicate, starches, such as maize, wheat, rice or arrow root starch, ~:
~' ~
-` 10~
gelatin , tragacanth 9 methyl cellulose, sodium carboxymethyl cellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorption agents, colourants, flavouring matters and sweeteners. It is also possible to use the novel pharma-cologically active compounds in the form of preparationswhich can be administered by injection, for example, by intravenous injection, or of infusion solutions. Such solutions are pre-ferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations that contain the active substance alone or together with a carrier, for example mannitol.
The pharmaceutical preparations, can be sterilised and/or contain adjuvants, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubility promoters,salts for regulating the osmotic pressure and/or buffers~Thepharma ceutical prepara~ions which, if desired, can contain further pharmacologically useful substances, are manufactured in known manner, for example using conventional mixing, granulating, `;
confectioning, dissolving or lyophilising methods, and they contain from 0.1% to 'oo%, especially from l~ to 50%t and ~-~
lyophilisates up to loo~ of the active substance. In partic- ;
ular, pharmaceutical preparations are prepared as dosage units. ~;`
~' 1~ ''l57' - ~o -Throughout the description and in the Examples, for the sake of clarity the nomenclature of the corresponding compounds is derived from bicyclomycin [systematic name: 6-hydroxy-5-methylene-(1',2',3'-trihydroxy-2'-methylpropyl)-2-oxa-7,9-diazabicyclo[4,2,2]decane-8,10-dione] or from 5-norbicyclom-ycin-5-one [systematic name: 6-hydroxy-1-(1',2',3'-trihydroxy-2'-methylpropyl)-2-oxa-7,9-diazabicyclo[4,2,2]decane-5,8,10-trione] as basic substance.
The following Examples will serve to illustrate the invention. ;~
Preparation of the startin~ materials ~;-A) A flow of ozone-enriched oxygen is introduced at -70Cat a speed of approx. 20 litres/hr into a solution of 8 g of bi-cyclomycin monohydrate in 350 ml of methanol. After about 45 minutes, when a permanent blue colouration ensues,2.2 ml of dimethyl sulphide are added and the reaction mixture isbrought gradually to 0C. The crystallised product is collected with suction and the mother liquor is concentrated to about a third of its volume and allowed to stand in order to obtain the second crop of crystals of the same quality. The resultant 5-nor-bicyclomycin-5~one has a melting point of 160-162C, which rises to 171-175C after c~ystallisation from ethyl acetate-methanol.
.
~' ~
1~394S~7 B) A solution of 11.5 g of bicyclomycin-6,1',3'-t~i-tetrahydro-pyranyl ether in 200 ml of methanol is ozonised as described in A) and treated with dimethyl sulphide. After it has warmed to room temperature, the reaction mixture is concentrated and the residue dissolved in a very small amount of ether. The solution is added dropwise into petroleum ether and the white amorphous precipitate is collected with suction and dried in a high vacuum. The resultant 5-nor-bicyclomycin-5-one-6,1',3'-tri-tetrahydropyranyl ether melts unsharp between 65 to 75C.
C) 3 g of bicyclomycin-3'-benzoate in methanolic solution are ozonised under the conditions of A). The excessozone isdestroyed with dimethy:L sulphide and the solution is concentrated in a waterjetvacuum. The residue is precipitated from methanol with ethyl acetate and yields amorphous 5-nor-bicyclomycin-5-one-3 benzoate with a melting point o~ 125-130C.
'''-, ' ~,' ~ '' . 1~7 ;';
: . . - .- - - ~ . .. : , . ~ .
~ 7 Example 1 A mixture of 2.43 g of 5-nor-bicyclomycin-5-one in 160 ml of ethanol and 0.75 ml of pyridine is treated with 0.56 g of hydroxylamine hydrochloride and heated, with stirring, to 60C
until, after approx. 1 hour, thin-layer chromatography reveals that no more starting material is present.The reactionmixture is concentrated and chromatographed over 100 g of silica gel.
The product is eluted with a 1:1 mixture (v/v) of chloroform and methanol and crystallised from methanol. Additional crys-tallisation ~rom methanol/ethyl acetate affords 5-hydroxy~
imino-5-nor-bicyclomycin, which melts at 185-1~7C(with de-composition); []D= ~ 19 ~ 1 tc 0.95; water).
,`, Example 2 Following the procedure described in Example 1, a mixture of 18.24 g o 5-norbicyclomycin-5-one, 5.02 g of 0-methylhydroxyl-amine hydrochloride, 5 ml of pyridine and 1250 ml of ethanol is stirred for 30 minutes at 60C and worked up. The crude pro~
duct is obtained by chromatography over 300 g of silicagel and ~lution with a 4:1 mixture (v/v) of chloroform/methanol. Re- ~-crystallisation from methanol/ethyl acetate gives 5-methoxy--imino-5-nor-bicyclomycin with a melting point of 165-168C.
., ......
~ .-. . . . .. . . . . .
J~
Example 3 _ Following the procedure described in Example 1, a mixture of 1.824 g of 5-norbicyclomycin-5-one, 0.957gofO-benzylhydroxyl-amine hydrochloride, 0.5 ml of pyridine and 120 ml of ethanol is stirred for 1 hour at 60C and worked up. The crude product ~. :
is obtained by chr~matography over 100 g of silica gel and elution with a 4:1 mixture (v/v~ of chloroform/methanol.Recrys-.tallisation frvm ethyl acetategives S-benzyl-oxyimino-5-nor-bicyclomycin with a melting point of 108-110C; [~]D =
+ 18 + 1 (c- 1.1; dioxane), :. -,'`,. ~
Example 4 ',`: '',:
Following the procedure described in Example 1, a mixture of ~.
0.608 g of 5-nor-bicyclomycin-5-one, 0.283 g of 0-methoxy-carbonylmethylhydroxylamine hydrochloride, 0.65 ml of pyridine ~:.
and 40 ml of ethanol is s~irred for 1 hour at 50C and.pH 7-8 and further worked up. The crude productis obtainedby chromato-graphy over 30 g of si.lica gel and elu~ion with a 4:1 mixture :
(v/v) of chloroform/methanol. Recrystallisation from ethyl acetate gives 5-methoxycar~onylmethoxyimino-5-nor-bicyclomycin with a melting point of 150-151C.
,. .
, ~ :
1V~ S7 Example 5 A suspension of 2.43 g of 5-nor-bicyclomycin-5-one and 1.16 g of phenylhydrazine hydrochloride in 0.675 ml of pyridine and 160 ml of ethanol is stixred at room temperature until a clear solution formsand thin-layerchromatography revealsthatno more starting material is present. l~e solution is concentrated in-a water jet vacuum and the residue is recrystallised from , . . . . ... .. . . .. .. . .. .. ... . . . . .. . . .
methanol to give 5-nor-bicyclomycin-5-one phenylhydrazone, which melts at 160C (with decomposition); ~JD = ~ 76 + 1 '`
(c - 0.97; dioxane); ~ max' 282 and 302 ~ ( = 16300 and 13300 respec~ively). ~`
Example 6 A clear solution of 0.446 g of semicarbazide hydrochloride in 80 ml of ethanol is treated at 90C (bath temperature) with 0.33 ml o~ pyridine and then with 1.21gof5-nor-bicyclomycin- `
5-one, and the reaction mixture is allowed to stand for 1 hour at this bath temperature. The product, which begins to preci-pitate in crystalline form while heating, crystallisesout com~
pletely on cooling and is then collected with suction and washed with a small amount of ethanol. The resultant 5-nor-bicyclomycin-S-one semicarbazone melts with dec~mposition at 195C; ~a]D = + 48 + 1 (c = 0.93; water) ~,.. `~.. `'i?.~ ';
~ 9 Example 7 A mixture of 5.7 g of 5-nor-bicyclomycin-5-one-3'-benzoate and 0.855 g of 0-methylhydroxylamine hydrochloride in 0.85 ml of pyridine and 150 ml of ethanol is stirred at 60C until, after
radicals are methoxymethyl, ethoxymethyl, 2-methoxyethyl and ~;
2-ethoxyethyl. ; -~.. ,~.. ~, ;
9~
g Carboxyl groups can be in the free form, as salts or as lower alkyl esters, in particular methyl and ethyl esters.
The novel compounds reveal useful pharmacological properties, as is shown both in the in vitro test and in animaltests.Thus the in vitro test results show them to have antibiotic, in particular antibac~erial, properties, for ex~mple against Enterobacteria (in concentrations of 0.025 to 0.5 mg/ml). In animal tests too, or against Proteus sp. (in concentrations of 0.1 to 0.5 mg/ml), for example on mice in doses of 16 to 100 mg/kg (subcutaneous administration) the novel com- ;
pounds show antibacterial properties against Escherichiacoli and Klebsiella, and, in doses of 20 to 700 mg/kg (subcuta~
neous administration), against Proteus sp. To be singled out for special mention is 5-methoxyimino-S-norbicyclomycin, i.e.
the compound of the formula IA, wherein -X-RA represents the methoxy group, for which an effective dose ED50 of 16 to ~`
20 mg/kg was found against Enterobacteria, for example Escherichia coli and Proteus sp., when administered subcuta-neously to mice. Bicyclomycin, to the contrary, is not suffi-ciently effective against Proteus. The novel compounds can therefore be used for example in the form of antibiotic preparations for the treatment of infectious diseases, or as preservatives, or as additives to animal feeds. In addition, ~
they can be used for the preparation of other compounds with ~-such an antibiotic action.
~ '~'' '' :' ~............................................................ ~;. ':`
L5 ~
The compounds of the formula I are obtained by reacting a 5-norbicyclomycin-S-one compound of the formula II
oRd O
/~ ' .~
~H ~ CH2 ,;
(~1 --0 / ( II) H--C--OR
CH3--C--oRb :,`.
wherein Ra, Rb, Rc and Rd are as defined in formula (I), with a co~pound of the formula . R-X-NH2 (III) .
wherein R and X are as already defined, or with a salt thereof, and, if desired, in a resultant compound~ removing or intro~
ducing one or more hydroxyl protectîve groups Ra, Rb, RCand/or Rd or converting them intoother hydroxylprotective gxoups,and,if ~ ~
desired, within the definition of the final products,converting ~ -a resul~ant compound into another compound, and/or,ifdesired, ~ :
converting a resultant compound with a salt forming group into the free compound or into another salt, and/or, if desired, ;~
s~parating individual isomers from a Fesultant isomer mixture. ~
':' `
:-. :- . -. :.. . -: : .. - . . : -, .. , . . ~ ~
Preferably, 5-norbicyclomycin-5-one, which has free hydroxyl groups, is used as s~arting material of the formula II.
Starting materials of the formula III are hydroxylamine and 0-substituted hydroxylamines of the formula R-O-NH2 (IIIa) wherein R is as defined above, and the corresponding acid addition salts. Starting materials of the formula III are also hydrazine or hydrazine hydrate and, in particular mono-substituted hydrazines, including semicarbazide, and the corresponding salts.
.~'.
They are characterised by the formula R
~-NH2 (IIIb) H
wherein R is as already defined herein. Salts of compounds of the formula III are primarily acid additions salts, in par-ticular with mineral acids, such as hydrohalic acids, for example hydrochloric or hydrobromic acid, or sulphuric acid.
: ` .
The above reaction is carried out in a manner known per se, `~
and, when using acid addition salts of compounds oftheormula ; III, in the presence o a basic reagent. Suitable bases are inorganic bases, such as carbonates or hydrogen carbonates of alkali metals or alkaline earth metals, for exa~ple sodium :~:
~. .,, ; ~ ~
`
hydrogen carbonate, or organic bases, for example tertiary organic bases, such as correspondin~ heterocyclic bases, for example pyridine or quinoline, or tertiary aliphatic, cyclo- :
aliphatic or aromatic amines, for example tri-loweralkylamine such as triethylamine, and also alkali metal or alkalineearth metal salts of organic carboxylic acids, such as lower alkane-carboxylic acids, for example acetic acid,such as sodium acetate. ~
The reaction is preferably carried out in the presence of a ~ ~.
suitable solvent or diluent, such as an alcohol, for example .
a lower alkanol, such as methanol or ethanol, an ether, such as a cyclic ether, for example tetrahydrofurane or dioxane, .
or an ether of a glycol, such as a lower alkyl etherof aglycol or polyglycol, for example ethylene glycol dimethyl ether or . .
diethylene glycol dimethyl ether, or a halogenatedhydrocarbon, such as a chlorinated alkane, for example methylene chloride, :
and water, or a solvent or diluent mixture) with cooling or ~.
preferably with heating, for exampl~3 at temperatures of 20 .
to 100C, and, if appropriate, in a closed reaction vessel ~-~
and/or in an inert gas atmosphere, for example in a nitrogen or argon atmosphere. ~ :
:'`~` ' In the process of the present invention and also in any addi-tional steps which it may be necessary to carry out, free ~unctional groups which are present in the starting materials .
~ ~4~ 5 or in the c~mpounds obtained in accordance with the process and which do not participate in the reaction, for example free amino groups in the group R, can, if necessary, be temporarily protected by acylation, tritylation or silylation, and, in particular, free hydroxyl groups in the bicyclomycin skeleton can be protected for example by etherification or esterifi-cation in a manner known per se, and, when the reaction is complete, set free, if desired, individually or together.
Thus, for example, hydroxyl groups which are protected as tetrahydropyranyl ether, for example in the 1'-, 3'- and/or 6-position, can be set free by conventional acid catalysed hydrolysis.
Resultant compounds of the formula I can be converted in a manner known per se into other compounds of the formula I.
For example, in a compound of the formula I, in which R in the grouping -NH-R represents hydrogen, and each of Ra, Rb and Rc is preferably different fr~m hydrogen~ the amino group can be substituted by methods which are known per se, in par~icular acylated, in a manner known per se, by treatment with acids, such as carboxylic acids, or reactive derivatives thereof, such as anhydrides, halides, for example chlorides, :~
and ketenes.
, ,. !; ~.
1~ ~ 9 ~ 5 7 It is also possible, for example in a compound ofthe formula I, wherein R in the grouping -O-R represents hydrogen, to substi-tute, preferably to alkylate, the free hydroxyl groupby methods which are known per se. In particular, a corresponding oxime with a free hydroxyl group can be treated in a mannerknown per se with a diaæoalkane, preferably diazomethane, preferably avoiding a large excess of the reactant and inappropriately long reaction tlmes.
Salts of compounds of the formula I càn be prepared in a manner ;~
known per se. Thus salts of compounds of the formula I with an acid grouping can be formed for example by treatment with metal~;
compounds, such as hydroxides, carbonates and hydrocarbonates of alkali metals or alkaline earth metals, andalsowith alkali ~`
metal salts of suitable carboxylic acids,for examplethe sodium salt of -ethylcaproic acid, or with ammonia or a suitable organic amine, preferably using stoichiometric amounts or only a small excess of the salt-forming agent. Acid addition salts ~
of compounds of the formula I with basic groups are obtained ~ ;
in similar manner, for example by treatment with an acid or a suitable anion exchanger. Inner salts of compounds o the formula I which contain a salt-forming amino group and a free carboxyl group, can be formed for example by neutralising salts, such as acid addition sal~s, to the isoelectric point, or example with weak bases, or by treatment with liquid ion exchangers.
-- . - , Salts can be converted in the cust:omary manner in~o the free compounds, metal and ammonium salts for example by treatment with suitable acids, and acid addition salts or example by treatment with a suitable base.
Resultant mixtures of stereoisomers can be separated into the individual isomers by methods which are known per se, for example by fractional crystallisation, adsorption chromato-graphy ~column or thin-layer chromatography), or other appropriate methods of separation.
The process also comprises those embodiments of the invention in which compounds obtained as intermediates are used as ~; `
starting materials and the remaining process steps are carried out therewith or in which the process is interrupted at any stage, or starting materials can be used in the form of deri-vatives or formed du_ing the reaction.
Preferably, the starting materials and reaction conditions are so chosen that the compounds referred to at the outset as~eing especially preferred are obtained.
The starting materials of the formula II used in accordance `
with the invention are novel They can be prepared forexamplc by oxidative elimination of the methylene group in a compound of the bicyclomycin type of the formula :.
'.
-- 16 - :
oRd ' ~' 2 ::~
~ ~H2 . ~
(~ /H2 ~ .. '' O (IV) H- C- ORa CH3- C - oRb wherein Ra9 Rb, Rc and Rd are as previously defined herein, and, if desired, in a resultant compound, introducing or-re-moving one or more hydroxyl protective groups Ra, Rb, Rc and/or .Rd or converting them into other hydroxyl protective groups. ::
The oxidative elimination of the methylene group can be accom~
plished in a manner known per se, for example byoxidatiDn with potassium permanganate or by hydroxylation, for example with osmi~m tetroxide, and subsequent glycol cleavage, or exampl with periodic acid or lead(IV) salts, the hydroxyl groups of the starting material being preferably protected and optionally ~ :
subsequently removed. Advan~ageously, the methylene group is removed by ozonisation, because, among other reasons, unpro~
tected hydroxyl groups are not affected.
. ;
"~
~0~3'~57 The ozonisation can be carried out in a manner known per se, for example by introducing a flow of oxygen which contains ozone into a solution of a bicyclomycin co~pound in a solvent which is inert to ozone until the theoretical amount of ozone has been consumed, and b~ decomposing the resultant ozonide thermally or by hydrolysis, reduction or oxida~ion. Suitable solvents ~or ozonisation are polyhalogenated, in particular chlorinated, lower alkanes, such as dichloromethane, chlorofo and dichloromethane, and in particular lower alkanols, such as me~hanol and ethanol, lower alkanecarboxylic acids,such as acetic acid, butyric acid, and preferably propionic acid, and the esters thereof with lower alkanols, such as ethyl acetate, as well as mixtures of such solvents. Preferred media are solvents and solvent mixtures which remain liquid even at low temperatures, for example below -20C and preferably also below -50C, and which still retain a good dissolving power for the -starting materials to be oæonised. ~he ozonisation is carried out at decreased temperature, for example between +10 and -80C, preferably between -18 and -70C. Normally the reac- ~ `~
tion is carried out with a small excess of ozone, which can be easily detected by the residual blue colouration of the reaction mixture. The decomposition of the resultantozonide is effected in the present process preferably by adding dimethyl sulphide, after which the reaction mixture isbrought ~`
to room temperature. The presence of water, for example of ;~
.~ ~' ., . .~ ~ _ __ _ _ _ _ . _ . .. .. _. __ _. _ _ _ .. ,. _ ,_ .
- ~o~
moisture or ~ater of crystallisation, does not affect these reactions.
~ree bicyclomycin of the formula IV, wherein Ra, ~b,RC and Rd represen~ hydrogen atoms, is.preferably used as starting material for the removal of the methylene group byozonolysis.
However, it is also possible to use corresponding derivatives, ;
fox example 1',3',6-tri-tetrahydropyranyl ether, with equal success.
The pharmacologically useful compounds of the present invention :;
can be used, for example, for the manufacture of pharmaceutlcal preparations which contain an effective amount of the active ;
substance together or in admixture with inorganic or organic ~:
solid or liquid pharmacologically useful carriers, which are suitable preferably for enteral or parenteral administration.
~ ~, Tablets or gelatin capsules are therefore used which contain the active substance together with diluents, for example lactose, dextrose, saccharose, mannitol, sorbitol, cellulose and/or glycin, and lubricants, for example silica, talc, stearic acid or salts thereof, such as magnesium or calcium :~
stearate, and/or polyethylene glycol. Tablets also contain binding agents, ~or example magnesium aluminium silicate, starches, such as maize, wheat, rice or arrow root starch, ~:
~' ~
-` 10~
gelatin , tragacanth 9 methyl cellulose, sodium carboxymethyl cellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorption agents, colourants, flavouring matters and sweeteners. It is also possible to use the novel pharma-cologically active compounds in the form of preparationswhich can be administered by injection, for example, by intravenous injection, or of infusion solutions. Such solutions are pre-ferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations that contain the active substance alone or together with a carrier, for example mannitol.
The pharmaceutical preparations, can be sterilised and/or contain adjuvants, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubility promoters,salts for regulating the osmotic pressure and/or buffers~Thepharma ceutical prepara~ions which, if desired, can contain further pharmacologically useful substances, are manufactured in known manner, for example using conventional mixing, granulating, `;
confectioning, dissolving or lyophilising methods, and they contain from 0.1% to 'oo%, especially from l~ to 50%t and ~-~
lyophilisates up to loo~ of the active substance. In partic- ;
ular, pharmaceutical preparations are prepared as dosage units. ~;`
~' 1~ ''l57' - ~o -Throughout the description and in the Examples, for the sake of clarity the nomenclature of the corresponding compounds is derived from bicyclomycin [systematic name: 6-hydroxy-5-methylene-(1',2',3'-trihydroxy-2'-methylpropyl)-2-oxa-7,9-diazabicyclo[4,2,2]decane-8,10-dione] or from 5-norbicyclom-ycin-5-one [systematic name: 6-hydroxy-1-(1',2',3'-trihydroxy-2'-methylpropyl)-2-oxa-7,9-diazabicyclo[4,2,2]decane-5,8,10-trione] as basic substance.
The following Examples will serve to illustrate the invention. ;~
Preparation of the startin~ materials ~;-A) A flow of ozone-enriched oxygen is introduced at -70Cat a speed of approx. 20 litres/hr into a solution of 8 g of bi-cyclomycin monohydrate in 350 ml of methanol. After about 45 minutes, when a permanent blue colouration ensues,2.2 ml of dimethyl sulphide are added and the reaction mixture isbrought gradually to 0C. The crystallised product is collected with suction and the mother liquor is concentrated to about a third of its volume and allowed to stand in order to obtain the second crop of crystals of the same quality. The resultant 5-nor-bicyclomycin-5~one has a melting point of 160-162C, which rises to 171-175C after c~ystallisation from ethyl acetate-methanol.
.
~' ~
1~394S~7 B) A solution of 11.5 g of bicyclomycin-6,1',3'-t~i-tetrahydro-pyranyl ether in 200 ml of methanol is ozonised as described in A) and treated with dimethyl sulphide. After it has warmed to room temperature, the reaction mixture is concentrated and the residue dissolved in a very small amount of ether. The solution is added dropwise into petroleum ether and the white amorphous precipitate is collected with suction and dried in a high vacuum. The resultant 5-nor-bicyclomycin-5-one-6,1',3'-tri-tetrahydropyranyl ether melts unsharp between 65 to 75C.
C) 3 g of bicyclomycin-3'-benzoate in methanolic solution are ozonised under the conditions of A). The excessozone isdestroyed with dimethy:L sulphide and the solution is concentrated in a waterjetvacuum. The residue is precipitated from methanol with ethyl acetate and yields amorphous 5-nor-bicyclomycin-5-one-3 benzoate with a melting point o~ 125-130C.
'''-, ' ~,' ~ '' . 1~7 ;';
: . . - .- - - ~ . .. : , . ~ .
~ 7 Example 1 A mixture of 2.43 g of 5-nor-bicyclomycin-5-one in 160 ml of ethanol and 0.75 ml of pyridine is treated with 0.56 g of hydroxylamine hydrochloride and heated, with stirring, to 60C
until, after approx. 1 hour, thin-layer chromatography reveals that no more starting material is present.The reactionmixture is concentrated and chromatographed over 100 g of silica gel.
The product is eluted with a 1:1 mixture (v/v) of chloroform and methanol and crystallised from methanol. Additional crys-tallisation ~rom methanol/ethyl acetate affords 5-hydroxy~
imino-5-nor-bicyclomycin, which melts at 185-1~7C(with de-composition); []D= ~ 19 ~ 1 tc 0.95; water).
,`, Example 2 Following the procedure described in Example 1, a mixture of 18.24 g o 5-norbicyclomycin-5-one, 5.02 g of 0-methylhydroxyl-amine hydrochloride, 5 ml of pyridine and 1250 ml of ethanol is stirred for 30 minutes at 60C and worked up. The crude pro~
duct is obtained by chromatography over 300 g of silicagel and ~lution with a 4:1 mixture (v/v) of chloroform/methanol. Re- ~-crystallisation from methanol/ethyl acetate gives 5-methoxy--imino-5-nor-bicyclomycin with a melting point of 165-168C.
., ......
~ .-. . . . .. . . . . .
J~
Example 3 _ Following the procedure described in Example 1, a mixture of 1.824 g of 5-norbicyclomycin-5-one, 0.957gofO-benzylhydroxyl-amine hydrochloride, 0.5 ml of pyridine and 120 ml of ethanol is stirred for 1 hour at 60C and worked up. The crude product ~. :
is obtained by chr~matography over 100 g of silica gel and elution with a 4:1 mixture (v/v~ of chloroform/methanol.Recrys-.tallisation frvm ethyl acetategives S-benzyl-oxyimino-5-nor-bicyclomycin with a melting point of 108-110C; [~]D =
+ 18 + 1 (c- 1.1; dioxane), :. -,'`,. ~
Example 4 ',`: '',:
Following the procedure described in Example 1, a mixture of ~.
0.608 g of 5-nor-bicyclomycin-5-one, 0.283 g of 0-methoxy-carbonylmethylhydroxylamine hydrochloride, 0.65 ml of pyridine ~:.
and 40 ml of ethanol is s~irred for 1 hour at 50C and.pH 7-8 and further worked up. The crude productis obtainedby chromato-graphy over 30 g of si.lica gel and elu~ion with a 4:1 mixture :
(v/v) of chloroform/methanol. Recrystallisation from ethyl acetate gives 5-methoxycar~onylmethoxyimino-5-nor-bicyclomycin with a melting point of 150-151C.
,. .
, ~ :
1V~ S7 Example 5 A suspension of 2.43 g of 5-nor-bicyclomycin-5-one and 1.16 g of phenylhydrazine hydrochloride in 0.675 ml of pyridine and 160 ml of ethanol is stixred at room temperature until a clear solution formsand thin-layerchromatography revealsthatno more starting material is present. l~e solution is concentrated in-a water jet vacuum and the residue is recrystallised from , . . . . ... .. . . .. .. . .. .. ... . . . . .. . . .
methanol to give 5-nor-bicyclomycin-5-one phenylhydrazone, which melts at 160C (with decomposition); ~JD = ~ 76 + 1 '`
(c - 0.97; dioxane); ~ max' 282 and 302 ~ ( = 16300 and 13300 respec~ively). ~`
Example 6 A clear solution of 0.446 g of semicarbazide hydrochloride in 80 ml of ethanol is treated at 90C (bath temperature) with 0.33 ml o~ pyridine and then with 1.21gof5-nor-bicyclomycin- `
5-one, and the reaction mixture is allowed to stand for 1 hour at this bath temperature. The product, which begins to preci-pitate in crystalline form while heating, crystallisesout com~
pletely on cooling and is then collected with suction and washed with a small amount of ethanol. The resultant 5-nor-bicyclomycin-S-one semicarbazone melts with dec~mposition at 195C; ~a]D = + 48 + 1 (c = 0.93; water) ~,.. `~.. `'i?.~ ';
~ 9 Example 7 A mixture of 5.7 g of 5-nor-bicyclomycin-5-one-3'-benzoate and 0.855 g of 0-methylhydroxylamine hydrochloride in 0.85 ml of pyridine and 150 ml of ethanol is stirred at 60C until, after
3 1/2 hours, thin-layer chromatography reveals that no more -starting material is present. The solution is concentrated and the residue is chromatographed over 100 g of silica gel.Elution ~`
with a 4:1 mixture (v/v) of chloroform/methanolgives 5-methoxy- -imino-5-nor-bicyclomycin-3'-benzoate, which is purified by precipitation from a solution of ethylacetate/ether. After it has been dried in a high vacuum, the product melts at 104-110C.
Example 8 A mixture of 4 g of 5-nor-bicyclomycin-5-one-6,1',3'-tri-tetrahydropyranyl ether and 0.60 g of 0-methylhydroxylamine hydrochloride in 0.576 ml of pyridine and 100 ml of ethanol is stirred at 60C until, after 2 1/2 hours, thin-layer chro-matography shows that no more starting materialis present. The solution is concentrated and the residue, which consists of crude 5-methoxyimino-5-nor-bicyclomycin-6,1',3'-tri-tetrahydro-pyranyl ether, is dissolved in 30 ml of methanol. Then 20 ml ;
of 50% (v/v) aqueous acetic acid are added and the mixture is stirred for 30 minutes at room temperature and concentrated in a water jet vacuum. The residue îs chromatographed over 100 g of silica gel and elution with a 4:1 mixture (v/v) of chloro-.~i ~ ~ .
fJ~7 form/methanol yields a crude product which, after recrystalli-sation from methanol/ethyl acetate, melts at 165-168C and is identical with the 5-methoxyimino-5-nor-bicyclomycin of Example 2.
Example 9 A solution of 1.824 g of 5-nor-bicyclomycin-5-one in 120 ml of ethanol is treated under reflux with 1.125 g of pyridinio-acetohydrazide chloride (Girard reagent P). The clear solution is heated for a further 30 minutes and then allowed to cool, ~`
After the solution has stood for about 2 hours at room tempera-ture, the product begins to crystallise~Recry~tallisation from methanol/ethyl acetate gives the pyridinioacetylhydrazone chloride of 5-nor-bicyclomycin with a melting point of 182-185C.
Example 10 Following the procedure described in Example 1~ a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 1.31 g of 0-carboxymethyl-hydroxylamine hemihydrochloride, 2 ml of pyridine and 120 ml of ethanol is stirred for 90 minutes at 60C and concentrated.
The crystallised product is purified by chr~matograp7ny over ;`~
silica gel and elution with a 4:1 mixture (v/v) of chloroform/
methanol. Recrystallisation from methanol gives 5-carboxy-methoxyimino-S-nor-bicyclomycin with a melting point of 160-163C; []D ~ + 28 ~ 10 (c = 0.896; water).
. ;
.:
~'~
t~
Example 11 :~' Following the procedure described in Example 13 a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 0.720 g of 0-(2-hydroxy~
ethyl)-hydroxylamine hydrochloride, 120 ml of ethanol and 0.72 ml of pyridine is stirred for 2 1/4 hours and concen-~rated. The product is purified by chromatography over silica gel and elution with a 4:1 mixture (v/v)ofchloroform/methanol.
Precipitation from methanol/ethyl acetate yields amorphous 5-(2-hydroxyethoxyimino)-5-nor-bicyclomycin with a melting polnt of 88-94C; ~]D = + 19 + 1 (c~0.644; dioxane).
Example 12 Following the procedure described in Example 1, a mixture of 1.82 g of 5-nor-bicyclomycin-5~one~ 1.15 g of 0-(2-dimethyl- ;
aminoethyl)-hydroxylamine hydrochloride, 120 ml of ethanol and 2.5 ml of pyridine is stirred ~or 2 1/4 hours at 50C. On cooling, the product separates out in crystalline form. Recrys~
tallisation from ethanol gives 5-(2-dimethylamino-ethoxyimino~
5-nor-bicyclomycin hydrochloride with a melting point of 210C
(with decomposition); [~]D = + 12 + 1 (c = 1.160; water).
~`;
~'~
', ~ ' s~
Example 13 A mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 0 921 g of dime~hylamino-acetohydrazide (Girard reagent D), 120 ml of ethanol and 1 mlof pyridine is heated,with stirring,to reflux.
After 20 minutes a crystalline product begins to precipitate.
After cooling, the crystals are collected with suctionand re-crystallised rom methanol/ethyl acetate to give5-nor-blcyclo-mycin-5-one-dimethylaminoacetylhydrazon with a mel'ing point of 188C (with decomposition); [a]D = + 31 + 1 (c =l.OO;
water).
Example 14 Following the procedure described in Example 1, a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 1.11 g of tosylhydrazide tp-toluenesulphonic acid hydrazide) and 100 ml of ethanol is heated for 4 hours to 50C and thereafter concentrated. The `~
product is purified by chromatography over silica gel and elution with a 4:1 mixture (v/v) of chloroform/methanol. Re-crystallisation from methanol gives 5-nor-bicyclomycin-5-one tosylhydrazone with a melting point of 185-186C ~with decom-position); []D = ~ 33 + 1 (c = 1.001; water).
. :
. . " , ~. . " .. . . . .....
~0~
Example 15 Following the procedure described in Example 1, a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 1.1 g of isonicotino-hydrazide (4-pyridine carbohydrazide) and 60 ml of ethanol is heated for 4 hours to 50C and thereafter concentrated. The product is purified by chromatography over silica gel and ~;
elution with a 2:1 mixture (v/v) of chloro~orm/methanol,affor-ding the 4-pyridinecarbohydrazone of 5-nor-bicyclomycin-5-one with a melting point of 161-165C twith decomposition, []D ~ + 19 + 1 (c = 0.889; water).
Example 16 :`
A solution of 2.73 g of 5-nor-bicyclomycin-5-one and 1.04 g of ~.
ethyl carbazate ~H2N.NH.CO.OC2H5) in 60 ml of dioxane is treated with 0.15 ml of acetic acid and stirred for 7 hours ~ -at 60C. The reaction mixture is concentrated in vacuo and the residue is chromatographed over silica gel and elution is effected with a 4:1 mixture (v/v) of chloroform/methanol~ ~
giving the amorphous ethoxycarbohydrazoneof5-nor-bicyclomycin- ~-5-one with a melting point of 140-143 ; ~]D ~ + 34 + 1 (c - 1.017; water).
, .
~ " , .
.
~ " , ~ ~ ~. } ~
' ' '',',; ' ~v~s~
Example 17 A mixture of 2 ml of isobutyl chloroformate and 20 ml oftetra-hydrofurane is added dropwise in the course of 20 minutes to a ~igorously stirred solution of 2 g of 5-methoxyi~ino-5-nor-bicyclomycin in 30 ml of pyridine which has been cooled to -15C. The mixture is subsequently stirred for 1/2 hour at -10C and then the precipitated pyridine hydrochloride is re-moved by ~iltration. The residual solution is concentrated in a high vacuum. Chromatography of the residue over silica gel with chloroform/methanol 19:1 as eluant yields two components:
the more rapidly eluted 5-methoxyimino-5-nor-bicyclomycin 1',3'-carbonate and the more slowly eluted amorphous 3l-0-iso-butyloxycarbonyl-5-methoxyimino-5-nor-bicyrl~mycin;
[]D = + 39 -~ 1(c - 0.725; dimethyl sulphoxide).
`~ ` . ' .,
with a 4:1 mixture (v/v) of chloroform/methanolgives 5-methoxy- -imino-5-nor-bicyclomycin-3'-benzoate, which is purified by precipitation from a solution of ethylacetate/ether. After it has been dried in a high vacuum, the product melts at 104-110C.
Example 8 A mixture of 4 g of 5-nor-bicyclomycin-5-one-6,1',3'-tri-tetrahydropyranyl ether and 0.60 g of 0-methylhydroxylamine hydrochloride in 0.576 ml of pyridine and 100 ml of ethanol is stirred at 60C until, after 2 1/2 hours, thin-layer chro-matography shows that no more starting materialis present. The solution is concentrated and the residue, which consists of crude 5-methoxyimino-5-nor-bicyclomycin-6,1',3'-tri-tetrahydro-pyranyl ether, is dissolved in 30 ml of methanol. Then 20 ml ;
of 50% (v/v) aqueous acetic acid are added and the mixture is stirred for 30 minutes at room temperature and concentrated in a water jet vacuum. The residue îs chromatographed over 100 g of silica gel and elution with a 4:1 mixture (v/v) of chloro-.~i ~ ~ .
fJ~7 form/methanol yields a crude product which, after recrystalli-sation from methanol/ethyl acetate, melts at 165-168C and is identical with the 5-methoxyimino-5-nor-bicyclomycin of Example 2.
Example 9 A solution of 1.824 g of 5-nor-bicyclomycin-5-one in 120 ml of ethanol is treated under reflux with 1.125 g of pyridinio-acetohydrazide chloride (Girard reagent P). The clear solution is heated for a further 30 minutes and then allowed to cool, ~`
After the solution has stood for about 2 hours at room tempera-ture, the product begins to crystallise~Recry~tallisation from methanol/ethyl acetate gives the pyridinioacetylhydrazone chloride of 5-nor-bicyclomycin with a melting point of 182-185C.
Example 10 Following the procedure described in Example 1~ a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 1.31 g of 0-carboxymethyl-hydroxylamine hemihydrochloride, 2 ml of pyridine and 120 ml of ethanol is stirred for 90 minutes at 60C and concentrated.
The crystallised product is purified by chr~matograp7ny over ;`~
silica gel and elution with a 4:1 mixture (v/v) of chloroform/
methanol. Recrystallisation from methanol gives 5-carboxy-methoxyimino-S-nor-bicyclomycin with a melting point of 160-163C; []D ~ + 28 ~ 10 (c = 0.896; water).
. ;
.:
~'~
t~
Example 11 :~' Following the procedure described in Example 13 a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 0.720 g of 0-(2-hydroxy~
ethyl)-hydroxylamine hydrochloride, 120 ml of ethanol and 0.72 ml of pyridine is stirred for 2 1/4 hours and concen-~rated. The product is purified by chromatography over silica gel and elution with a 4:1 mixture (v/v)ofchloroform/methanol.
Precipitation from methanol/ethyl acetate yields amorphous 5-(2-hydroxyethoxyimino)-5-nor-bicyclomycin with a melting polnt of 88-94C; ~]D = + 19 + 1 (c~0.644; dioxane).
Example 12 Following the procedure described in Example 1, a mixture of 1.82 g of 5-nor-bicyclomycin-5~one~ 1.15 g of 0-(2-dimethyl- ;
aminoethyl)-hydroxylamine hydrochloride, 120 ml of ethanol and 2.5 ml of pyridine is stirred ~or 2 1/4 hours at 50C. On cooling, the product separates out in crystalline form. Recrys~
tallisation from ethanol gives 5-(2-dimethylamino-ethoxyimino~
5-nor-bicyclomycin hydrochloride with a melting point of 210C
(with decomposition); [~]D = + 12 + 1 (c = 1.160; water).
~`;
~'~
', ~ ' s~
Example 13 A mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 0 921 g of dime~hylamino-acetohydrazide (Girard reagent D), 120 ml of ethanol and 1 mlof pyridine is heated,with stirring,to reflux.
After 20 minutes a crystalline product begins to precipitate.
After cooling, the crystals are collected with suctionand re-crystallised rom methanol/ethyl acetate to give5-nor-blcyclo-mycin-5-one-dimethylaminoacetylhydrazon with a mel'ing point of 188C (with decomposition); [a]D = + 31 + 1 (c =l.OO;
water).
Example 14 Following the procedure described in Example 1, a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 1.11 g of tosylhydrazide tp-toluenesulphonic acid hydrazide) and 100 ml of ethanol is heated for 4 hours to 50C and thereafter concentrated. The `~
product is purified by chromatography over silica gel and elution with a 4:1 mixture (v/v) of chloroform/methanol. Re-crystallisation from methanol gives 5-nor-bicyclomycin-5-one tosylhydrazone with a melting point of 185-186C ~with decom-position); []D = ~ 33 + 1 (c = 1.001; water).
. :
. . " , ~. . " .. . . . .....
~0~
Example 15 Following the procedure described in Example 1, a mixture of 1.82 g of 5-nor-bicyclomycin-5-one, 1.1 g of isonicotino-hydrazide (4-pyridine carbohydrazide) and 60 ml of ethanol is heated for 4 hours to 50C and thereafter concentrated. The product is purified by chromatography over silica gel and ~;
elution with a 2:1 mixture (v/v) of chloro~orm/methanol,affor-ding the 4-pyridinecarbohydrazone of 5-nor-bicyclomycin-5-one with a melting point of 161-165C twith decomposition, []D ~ + 19 + 1 (c = 0.889; water).
Example 16 :`
A solution of 2.73 g of 5-nor-bicyclomycin-5-one and 1.04 g of ~.
ethyl carbazate ~H2N.NH.CO.OC2H5) in 60 ml of dioxane is treated with 0.15 ml of acetic acid and stirred for 7 hours ~ -at 60C. The reaction mixture is concentrated in vacuo and the residue is chromatographed over silica gel and elution is effected with a 4:1 mixture (v/v) of chloroform/methanol~ ~
giving the amorphous ethoxycarbohydrazoneof5-nor-bicyclomycin- ~-5-one with a melting point of 140-143 ; ~]D ~ + 34 + 1 (c - 1.017; water).
, .
~ " , .
.
~ " , ~ ~ ~. } ~
' ' '',',; ' ~v~s~
Example 17 A mixture of 2 ml of isobutyl chloroformate and 20 ml oftetra-hydrofurane is added dropwise in the course of 20 minutes to a ~igorously stirred solution of 2 g of 5-methoxyi~ino-5-nor-bicyclomycin in 30 ml of pyridine which has been cooled to -15C. The mixture is subsequently stirred for 1/2 hour at -10C and then the precipitated pyridine hydrochloride is re-moved by ~iltration. The residual solution is concentrated in a high vacuum. Chromatography of the residue over silica gel with chloroform/methanol 19:1 as eluant yields two components:
the more rapidly eluted 5-methoxyimino-5-nor-bicyclomycin 1',3'-carbonate and the more slowly eluted amorphous 3l-0-iso-butyloxycarbonyl-5-methoxyimino-5-nor-bicyrl~mycin;
[]D = + 39 -~ 1(c - 0.725; dimethyl sulphoxide).
`~ ` . ' .,
Claims (19)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for the manufacture of a 2-oxa-7,9-diazabicyclo[4,2,2]decane derivative of the formula (I) wherein each of Ra, Rb, Rc and Rd individually represents hydrogen atom or oxa-(lower alkyl), oxa-(lower cycloalkyl), lower alkanoyl, benzoyl, lower alkoxycarbonyl, or any two of the symbols Ra, Rb and Rc together represent carbonyl, lower alkylidene, or lower cycloalkylidene, R represents hydrogen, lower alkyl, a lower alkyl which is substituted by hydroxy, lower alkoxy, lower alkanoyloxy, amino, di-(lower alkyl)-amino, carboxy or lower alkoxycarbonyl, or represents phenyl or phenyl-(lower alkyl), or a phenyl or a phenyl-(lower alkyl) whose ring is substituted by halo-gen, nitro, lower alkyl or lower alkoxy, or represents an acyl derived from a lower alkanesulfonic acid, benzenesul-fonic acid, a benzenesulfonic acid whose phenyl ring is substituted as indicated hereinabove, or an acyl derived from a carbonic acid amide or (lower alkyl)-monoester or from a carboxylic acid derived from any of the above-defined unsubstituted or substituted lower alkyl, phenyl or phenyl-(lower alkyl) radicals or from a pyridyl or pyri-dinio-(lower alkyl) radical, and X represents a bivalent group of the formula -O- or -NH-, and of pharmaceutically acceptable salts of such a compound, provided it contains a salt-forming group, which process com-prises reacting a compound of the formula (II) wherein Ra, Rb, Rc and Rd are as defined in formula (I) above, with a compound of the formula R - X - NH2 (III) in which R and X are as defined in formula (I) above, or with a salt thereof, and, if a compound is required in which any of the symbols Ra, Rb, Rc and Rd represents hydrogen, subjec-ting to hydrolysis a resulting compound in which one or more of the symbols Ra, Rb, Rc and Rd represent a hydroxyl protec-tive group as defined hereinabove, and/or, if required, con-verting a resultant compound containing a salt-forming group into a pharmaceutically acceptable salt or a resultant salt into the free compound or into another pharmaceutically acceptable salt, and/or, if required, separating one indivi-dual isomer from a resulting isomer mixture.
2. A process according to claim 1, wherein start-ing materials are selected so as to produce a compound of the formula I, wherein X represents the group -O- and the other symbols are as defined in claim 1.
3. A process according to claim 1, wherein start-ing materials are selected so as to produce a compound of the formula I, wherein Rb represents hydrogen, each of Ra, Rc and Rd represents 2-tetrahydropyranyl, and the other symbols are as defined in claim 1.
4. A process according to claim 1, wherein starting materials are selected so as to produce a compound of the formula I, wherein Ra, Rb and Rd each represents hydrogen, Rc represents hydrogen atom, lower alkanoyl, benzoyl or lower alkoxycarbonyl, and the other symbols are as defined in claim 1.
5. A process according to claim 1, wherein starting materials are selected so as to produce a compound of the formula (IA) wherein RA represents a hydrogen atom, a lower alkyl, a lower alkyl which is substituted by hydroxy, lower alkoxy, lower alkanoyloxy, amino, di-(lower alkyl)-amino, carboxy or lower alkoxycarbonyl, or represents phenyl or phenyl-(lower alkyl), or a phenyl or a phenyl-(lower alkyl) whose ring is substituted by halo-gen, nitro, lower alkyl or lower alkoxy, or represents an acyl derived from a lower alkanesulfonic acid, benzenesul-fonic acid, a benzenesulfonic acid whose phenyl ring is substituted as indicated hereinabove, or an acyl derived from a carbonic acid amide or (lower alkyl)-monoester or from a carboxylic acid derived from any of the above-de-fined unsubstituted or substituted lower alkyl, phenyl or phenyl-(lower alkyl) radicals or from a pyridyl or pyridi-nio-(lower alkyl) radical, and X represents a group of the formula -O- or -NH-, or a pharmaceutically acceptable salt of such a compound, provided it contains a salt-forming group.
6. A process according to claim 5, wherein starting materials are selected so as to produce a compound of the formula (IA) wherein X represents the group -O- and RA
represents lower alkyl, phenyl-(lower alkyl), hydroxy-(lower alkyl), lower alkanoyloxy-(lower alkyl), di-(lower alkyl)-amino-(lower alkyl), carboxy-(lower alkyl) or hy-drogen.
represents lower alkyl, phenyl-(lower alkyl), hydroxy-(lower alkyl), lower alkanoyloxy-(lower alkyl), di-(lower alkyl)-amino-(lower alkyl), carboxy-(lower alkyl) or hy-drogen.
7. A process according to claim 5, wherein starting materials are selected so as to produce a compound of the formula IA, wherein X represents the group -NH- and RA re-presents hydrogen, lower alkyl, phenyl, a phenyl which is substituted by halogen, nitro, lower alkyl or lower alkoxy, or represents an acyl derived from a carbonic-acid amide or (lower alkyl)-monoester, from benzenesulfonic acid, from a benzenesulfonic acid substituted by halogen, nitro or lower alkyl, from a pyridinecarboxylic acid, from lower alkanoic acid or a lower alkanoic acid substituted with phenyl, di(lower alkyl)-amino or a pyridyl.
8. A process according to claim 1, wherein starting materials are selected so as to produce a compound of the formula I wherein =N-X-R represents hydroxyimino, lower alkoxyimino, phenyl-(lower alkoxy)-imino- or lower alkoxy-carbonylmethoxyimino.
9. A process according to claim 1, wherein starting materials are selected so as to produce a compound of the formula I wherein =N-X-R represents phenylhydrazo, semi-carbazo or pyridinio-(lower alkanoyl)-hydrazo.
10. A process according to claim 1, wherein starting materials are selected so as to produce a compound of the formula I wherein =N-X-R represents carboxy-(lower alkoxy)imino, hydroxy-(lower alkoxy)imino or di-(lower alkyl)amino-(lower alkoxy)imino.
11. A process according to claim 1, wherein starting materials are selected so as to produce a compound of the formula I wherein =N-X-R represents di(lower alkyl)amino-acetylhydrazo, lower alkoxycarbonylhydrazo, isonicotinoyl-hydrazo or tosylhydrazo.
12. A process according to claim 1, wherein starting materials are selected so as to produce a compound, which is selected from a group consisting of the following com-pounds: 5-benzyloxyimino-5-nor-bicyclomycin; 5-carboxy-methoxyimino-5-nor-bicyclomycin; 5-methoxyimino-5-nor-bicyclomycin-6,1',3'-tri-tetrahydropyranyl ether; 5-nor-bicyclomycin-5-one phenylhydrazone, 5-nor-bicyclomycin-5-one semicarbazone, and 5-nor-bicyclomycin-5-one pyri-dinioacetylhydrazone chloride.
13. A process according to claim 1, wherein 5-nor-bicyclomycin-5-one is reacted with hydroxylamine to pro-duce 5-hydroxyimino-5-nor-bicyclomycin.
14. A process according to claim 1, wherein 5-nor-bicyclomycin-5-one is reacted with O-methylhydroxylamine to produce 5-methoxyimino-5-nor-bicyclomycin.
15. A process according to claim 1, wherein 5-nor-bicyclomycin-5-one is reacted with O-methoxycarbonylmethyl-hydroxylamine to produce 5-methoxycarbonylmethoxyimino-5-nor-bicyclomycin.
16. A process according to claim 1, wherein 5-nor-bicyclomycin-5-one 3'-benzoate is reacted with O-methyl-hydroxylamine to produce 5-methoxyimino-5-nor-bicyclomycin 3'-benzoate.
17. An 2-oxa-7,9-diazabicyclo[4,2,2]decane deri-vative of the formula wherein each of Ra, Rb, Rc and Rd individually represents hydrogen atom or oxa-(lower alkyl), oxa-(lower cycloalkyl), lower alkanoyl, benzoyl, lower alkoxycarbonyl, or any two of the symbols Ra, Rb and Rc together represent carbonyl, lower alkylidene, or lower cycloalkylidene, R represents hydrogen, lower alkyl, a lower alkyl which is substituted by hydroxy, lower alkoxy, lower alkanoyloxy, amino, di-(lower alkyl)-amino, carboxy or lower alkoxycarbonyl, or represents phenyl or phenyl-(lower alkyl), or a phenyl or a phenyl-(lower alkyl) whose ring is substituted by halogen, nitro, lower alkyl or lower alkoxy, or represents an acyl derived from a lower alkanesulfonic acid, benzene-sulfonic acid, a benzenesulfonic acid whose phenyl ring is substituted as indicated hereinabove, or an acyl derived from a carbonic acid amide or (lower alkyl)-monoester or from a carboxylic acid derived from any o? the above-de-fined unsubstituted or substituted lower alkyl, phenyl or phenyl-(lower alkyl) radicals or from a pyridyl-or pyridi-nio-(lower alkyl) radical, and X represents a bivalent group of the formula -O- or -NH-, or a pharmaceutically acceptable salt thereof, provided that the compound contains a salt-forming group, whenever prepared by the process of claim 1 or by any obvious chemical equivalent thereof.
18. 5-Hydroxyimino-5-nor-bicyclomycin, whenever prepared by the process of claim 13 or by any obvious chemical equivalent thereof.
19. 5-Methoxyimino-5-nor-bicyclomycin, whenever prepared by the process of claim 14, or by any obvious chemical equivalent thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH6445/76 | 1976-05-21 | ||
CH644576 | 1976-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1089457A true CA1089457A (en) | 1980-11-11 |
Family
ID=4309746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA278,748A Expired CA1089457A (en) | 1976-05-21 | 1977-05-19 | 5-nor-bicyclomycin-5-one derivatives |
Country Status (14)
Country | Link |
---|---|
US (1) | US4322419A (en) |
JP (1) | JPS52142092A (en) |
AT (1) | AT350720B (en) |
AU (1) | AU510339B2 (en) |
BE (1) | BE854841A (en) |
CA (1) | CA1089457A (en) |
DE (1) | DE2722164A1 (en) |
DK (1) | DK221377A (en) |
ES (1) | ES458932A1 (en) |
FR (1) | FR2351981A1 (en) |
GB (1) | GB1545021A (en) |
NL (1) | NL7705595A (en) |
SE (1) | SE7705884L (en) |
ZA (1) | ZA773018B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5452731A (en) * | 1977-09-14 | 1979-04-25 | Fujisawa Pharmaceut Co Ltd | Animal growth accelerator |
CA2072602A1 (en) * | 1989-12-27 | 1991-06-28 | Satoru Nakano | Drug for preventing and treating fish diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4829158B1 (en) * | 1970-10-12 | 1973-09-07 | ||
JPS4945093A (en) * | 1972-09-08 | 1974-04-27 | ||
GB1464962A (en) * | 1974-05-09 | 1977-02-16 | Fujisawa Pharmaceutical Co | Acyl derivatives of antibiotic ws-4545 |
GB1568961A (en) * | 1975-10-20 | 1980-06-11 | Fujisawa Pharmaceutical Co | Bicyclomycin derivatives |
LU75516A1 (en) * | 1976-08-02 | 1978-02-13 |
-
1977
- 1977-05-17 DE DE19772722164 patent/DE2722164A1/en not_active Withdrawn
- 1977-05-18 FR FR7715323A patent/FR2351981A1/en active Granted
- 1977-05-18 SE SE7705884A patent/SE7705884L/en unknown
- 1977-05-19 CA CA278,748A patent/CA1089457A/en not_active Expired
- 1977-05-19 GB GB21110/77A patent/GB1545021A/en not_active Expired
- 1977-05-19 ES ES458932A patent/ES458932A1/en not_active Expired
- 1977-05-20 NL NL7705595A patent/NL7705595A/en not_active Application Discontinuation
- 1977-05-20 JP JP5781877A patent/JPS52142092A/en active Pending
- 1977-05-20 AT AT361277A patent/AT350720B/en not_active IP Right Cessation
- 1977-05-20 BE BE177741A patent/BE854841A/en unknown
- 1977-05-20 ZA ZA00773018A patent/ZA773018B/en unknown
- 1977-05-20 DK DK221377A patent/DK221377A/en unknown
- 1977-05-20 AU AU25320/77A patent/AU510339B2/en not_active Expired
-
1979
- 1979-01-08 US US06/001,996 patent/US4322419A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES458932A1 (en) | 1978-08-16 |
DE2722164A1 (en) | 1977-12-22 |
FR2351981A1 (en) | 1977-12-16 |
DK221377A (en) | 1977-11-22 |
FR2351981B1 (en) | 1980-01-18 |
ATA361277A (en) | 1978-11-15 |
AU2532077A (en) | 1978-11-23 |
AU510339B2 (en) | 1980-06-19 |
SE7705884L (en) | 1977-11-22 |
ZA773018B (en) | 1978-04-26 |
AT350720B (en) | 1979-06-11 |
BE854841A (en) | 1977-11-21 |
US4322419A (en) | 1982-03-30 |
GB1545021A (en) | 1979-05-02 |
JPS52142092A (en) | 1977-11-26 |
NL7705595A (en) | 1977-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3275626A (en) | Penicillin conversion via sulfoxide | |
KR890000812B1 (en) | Epimerization of malonic acid esters | |
NO782866L (en) | PROCEDURE FOR PREPARATION OF CEPHALOSPORINE DERIVATIVES | |
NO171852B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE CEFEM COMPOUNDS WITH TWO SUBSTITUTED 5-RING RINGS | |
CH632513A5 (en) | METHOD FOR PRODUCING UNSATURATED DERIVATIVES OF 7-ACYLAMIDO-3-CEPHEM-4-CARBONIC ACID. | |
CA1089457A (en) | 5-nor-bicyclomycin-5-one derivatives | |
ZA200300472B (en) | Process for the preparation of highly pure crystalline (R,S)-cefuroxime axetil. | |
EP0137442A2 (en) | Cephalosporin derivatives and process for their preparation | |
SE461527B (en) | FLUOROMETHYLTHIO OXADETHYA PHALOSPORINES AND ANTIBACTERIAL COMPOSITION | |
US3696116A (en) | 1-(2-aminocarbonyloxyethyl)-5-nitro-imidazole derivatives having antiprotozoal activity | |
EP0144032B1 (en) | Cephalosporins and process for their preparation | |
Bohme et al. | 6-Alkylpenicillins and 7-alkylcephalosporins | |
EP0043756B1 (en) | 1,2,4-triazinylthiomethyl-3-cephem sulfoxides, process for their preparation and pharmaceutical compositions containing them | |
EP0115816B1 (en) | New aminoglycoside derivatives, processes for their preparation and pharmaceutical compositions containing them | |
JPS6135994B2 (en) | ||
Karady et al. | Synthesis of D-and L-. alpha.-(3, 4-dihydroxybenzyl)-. alpha.-hydrazinopropionic acid via resolution | |
US4482545A (en) | Isoefrotomycin, process of preparation, pharmaceutical composition and method of using same | |
US3937707A (en) | 6-substituted 1-phenazinol 5,10-dioxide derivatives | |
DE2818985C2 (en) | Halogenarylmalonamidooxacephalosporins and their use in combating bacterial infections | |
JP3012986B2 (en) | Cephem compound and method for producing the same | |
KR970010070B1 (en) | Cephem compounds | |
SU1604160A3 (en) | Method of producing compounds of cephem or their salts | |
US3852268A (en) | Inosine-5 -carboxylic acid amides | |
KR840002046B1 (en) | Process for preparing cepharosporins | |
KR810001134B1 (en) | Process for preparing thiadiazolylthio cephalosporins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |